Skip to content
Legal NAD

Research digest / 08

About this NAD+ readout.

Who publishes this, what it is, and — just as important — what it is not.

What the name means

The word 'legal' in the name is editorial framing, not a claim about services or a legal opinion. It points at a real feature of this subject: NAD+ and its common precursors are sold as dietary supplements rather than approved drugs, and the regulatory status of one precursor — NMN — is genuinely contested in the U.S. marketplace [13]. The name marks the position this publisher occupies relative to that literature — reading the supplement-and-regulatory record straight — not a service we offer. We do not sell NAD+, advise on buying it, or operate any pathway to obtain it.

How we handle accuracy

Two disciplines govern every page. First, the NAD+-versus-precursor distinction is kept exact: oral NAD+ is poorly absorbed, so a trial of NMN or NR is never described as 'taking NAD+', and every route-specific figure carries a channel tag (ORAL-PRECURSOR, IV, INJECTABLE). Second, we describe only what specific cited studies measured, in research framing — 'a trial of 250 mg/day NMN raised blood NAD+ and improved muscle insulin sensitivity' [11] — never a recommendation to use any product or dose. We do not claim NAD+ or any precursor treats, reverses, cures or prevents aging or any disease. Where the evidence is thin — IV NAD+, hard clinical endpoints, tissue-level NAD+ — we say so, citing the 2025 review that reached the same conclusion [14].

Corrections

If a citation is misattributed or a figure is wrong, we want to fix it. The studies cited here are real, indexed and linked; if you find an error, the contact page is the way to flag it. This is a digest of the literature, and the literature is the authority — not this site.